All patients with recurrent BC or mBC should be assessed for gBRCA1/2 mutations to identify candidates for targeted therapy.
Real-world analysis of 407 US adult patients with HER2- ABC showed gBRCA1/2 mutation testing was performed in only²*:
Lower gBRCA testing rates were observed in patients with HR+/HER2- ABC vs advanced TNBC, patients without a family history of BRCA-related cancers, and older patients²